

Supplemental Information

Title: HLA Correlations with Clinical Phenotypes and Risk of Metabolic Co-morbidities in Singapore Chinese Psoriasis Patients

Journal: Molecular Diagnosis & Therapy

Authors: M. Shen, S. W. D. Lim, E. S. Tan, H. H. Oon, E. C. Ren

Corresponding authors:

Name: Hazel H. Oon

Address: National Skin Centre (S) Pte Ltd

1 Mandalay Rd

Singapore 308205

Email: hazeloon@nsc.com.sg

Telephone: +65- 6253 4455

Name: Ee Chee Ren

Address: Singapore Immunology Network (SIgN)

8A Biomedical Grove, #03-06, Immunos Building

Singapore 138648

Email: ren_ee_chee@immunol.a-star.edu.sg

Telephone: +65-6407 0004

Table S1. Comparison of HLA-DRB1 allele frequencies between psoriasis and control populations¹

| Allele | Allele frequency | | |
|------------|-----------------------|----------------------|---------------------|
| | Psoriasis (2n=232) | Controls (2n=260) | Odds ratio (95% CI) |
| DRB1*01:01 | 2 (0.9) | 2 (0.8) | 1.12 (0.16 - 8.03) |
| DRB1*03:01 | 10 (4.3) | 25 (9.6) | 0.42 (0.20 - 0.90) |
| DRB1*04:03 | 6 (2.6) | 9 (3.5) | 0.74 (0.26 - 2.11) |
| DRB1*04:04 | 4 (1.7) | 3 (1.2) | 1.5 (0.33 - 6.79) |
| DRB1*04:05 | 19 (8.2) | 15 (5.8) | 1.46 (0.72 - 2.94) |
| DRB1*04:06 | 10 (4.3) | 7 (2.7) | 1.63 (0.61 - 4.35) |
| DRB1*07:01 | 0 (0.0) | 5 (1.9) | n.a. |
| DRB1*08:02 | 2 (0.9) | 3 (1.2) | 0.74 (0.12 - 4.50) |
| DRB1*08:03 | 22 (9.5) | 22 (8.5) | 1.13 (0.61 - 2.11) |
| DRB1*08:09 | 0 (0.0) | 4 (1.5) | n.a. |
| DRB1*09:01 | 53 (22.8) | 37 (14.2) | 1.78 (1.12 - 2.84) |
| DRB1*11:01 | 18 (7.8) | 16 (6.2) | 1.28 (0.64 - 2.58) |
| DRB1*12:01 | 3 (1.3) | 9 (3.5) | 0.37 (0.10 - 1.37) |
| DRB1*12:02 | 18 (7.8) | 29 (11.2) | 0.67 (0.36 - 1.24) |
| DRB1*13:02 | 1 (0.4) | 4 (1.5) | 0.28 (0.03 - 2.50) |
| DRB1*14:01 | 3 (1.3) | 9 (3.5) | 0.37 (0.10 - 1.37) |
| DRB1*14:04 | 2 (0.9) | 2 (0.8) | 1.12 (0.16 - 8.03) |
| DRB1*14:05 | 7 (3.0) | 4 (1.5) | 1.99 (0.58 - 6.89) |
| DRB1*14:54 | 7 (3.0) | 0 (0) | n.a. |
| DRB1*15:01 | 13 (5.6) | 23 (8.8) | 0.61 (0.30 - 1.24) |
| DRB1*15:02 | 9 (3.9) | 5 (1.9) | 2.06 (0.68 - 6.23) |
| DRB1*16:02 | 20 (8.6) | 18 (6.9) | 1.27 (0.65 - 2.46) |

n.a.: not applicable

¹Only alleles with a total count of more than three in the combined psoriasis-control dataset are displayed.

Table S2. Comparison of HLA-DRB1 genotype frequencies between psoriasis and control populations¹

| Allele | Genotype frequency | | Odds ratio (95% CI) |
|------------|------------------------|-----------------------|---------------------|
| | Psoriasis (n = 116) | Controls (n = 130) | |
| DRB1*01:01 | 2 (1.7) | 2 (1.5) | 1.12 (0.16 - 8.10) |
| DRB1*03:01 | 9 (7.8) | 22 (16.9) | 0.41 (0.18 - 0.94) |
| DRB1*04:03 | 4 (3.4) | 8 (6.2) | 0.54 (0.16 - 1.86) |
| DRB1*04:04 | 4 (3.4) | 3 (2.3) | 1.51 (0.33 - 6.90) |
| DRB1*04:05 | 18 (15.5) | 15 (11.5) | 1.41 (0.67 - 2.94) |
| DRB1*04:06 | 9 (7.8) | 7 (5.4) | 1.48 (0.53 - 4.10) |
| DRB1*07:01 | 0 (0.0) | 5 (3.8) | n.a. |
| DRB1*08:02 | 1 (0.9) | 3 (2.3) | 0.37 (0.04 - 3.59) |
| DRB1*08:03 | 21 (18.1) | 22 (16.9) | 1.09 (0.56 - 2.10) |
| DRB1*08:09 | 0 (0.0) | 4 (3.1) | n.a. |
| DRB1*09:01 | 45 (38.8) | 33 (25.4) | 1.86 (1.08 - 3.21) |
| DRB1*11:01 | 17 (14.7) | 16 (12.3) | 1.22 (0.59 - 2.55) |
| DRB1*12:01 | 3 (2.6) | 8 (6.2) | 0.4 (0.10 - 1.56) |
| DRB1*12:02 | 15 (12.9) | 27 (20.8) | 0.57 (0.28 - 1.13) |
| DRB1*13:02 | 1 (0.9) | 4 (3.1) | 0.27 (0.03 - 2.49) |
| DRB1*14:01 | 3 (2.6) | 8 (6.2) | 0.4 (0.10 - 1.56) |
| DRB1*14:05 | 7 (6.0) | 4 (3.1) | 2.02 (0.58 - 7.10) |
| DRB1*14:54 | 6 (5.2) | 0 (0) | n.a. |
| DRB1*15:01 | 12 (10.3) | 21 (16.2) | 0.6 (0.28 - 1.28) |
| DRB1*15:02 | 9 (7.8) | 3 (2.3) | 3.56 (0.94 - 13.49) |
| DRB1*16:02 | 19 (16.4) | 17 (13.1) | 1.3 (0.64 - 2.64) |

n.a.: not applicable

¹Only alleles with a total count of more than three in the combined psoriasis-control dataset are displayed.

Table S3. Three-locus haplotype analysis of psoriasis patients and control subjects

| Allele combination | Haplotype frequency (%) | | | | |
|----------------------------|-------------------------|------------------------|------|---------------|----------------------|
| | Psoriasis (2n = 232) | Controls (2n = 260) | OR | (95% CI) | P-value ¹ |
| A*02:07/B*46:01/C*01:02 | 42.2 | 19.2 | 3.07 | (1.74 - 5.44) | 0.05 |
| A*02:07/C*01:02/DRB1*09:01 | 28.4 | 10.0 | 3.58 | (1.78 - 7.21) | 0.15 |
| A*02:07/B*46:01/DRB1*09:01 | 26.7 | 10.0 | 3.28 | (1.62 - 6.65) | 0.45 |

¹P-values were corrected for multiple testing.

Table S4. Age of onset of psoriasis when specific HLA alleles are present/absent

| Allele | Age of onset (years) | | | |
|---------|----------------------|------|---------------|------|
| | Allele present | | Allele absent | |
| | Mean | SD | Mean | SD |
| A*02:07 | 31.7 | 13.2 | 29.6 | 14.1 |
| A*33:03 | 30.3 | 12.3 | 30.8 | 13.8 |
| B*46:01 | 31.7 | 12.8 | 29.9 | 14.3 |
| C*01:02 | 32.7 | 12.8 | 28.2 | 14.2 |
| C*06:02 | 27.8 | 15.6 | 31.2 | 13.2 |

Table S5. Difference in rates of homozygosity between psoriasis cases and controls

| Allele | Psoriasis | Controls | Difference (%) |
|---------|-----------|----------|----------------|
| | n (%) | n (%) | |
| A*02:07 | 8 (6.90) | 4 (3.08) | 3.8 |
| B*46:01 | 9 (7.76) | 5 (3.85) | 3.9 |
| C*01:02 | 10 (8.62) | 7 (5.38) | 3.2 |

Table S6. Correlations between HLA genotype frequencies and nail psoriasis and psoriatic arthritis

| Nail psoriasis | Psoriatic arthritis | Allele | Genotype frequency (%) of allele | | | | <i>P</i> -value ¹ |
|----------------|---------------------|---------|----------------------------------|-----------------|------|----------------|------------------------------|
| | | | Symptoms present | Symptoms absent | OR | (95% CI) | |
| Present | Absent | A*02:07 | 65.0 | 48.2 | 1.99 | (0.95 - 4.21) | n.s. |
| | | A*33:03 | 10.0 | 14.3 | 0.67 | (0.22 - 2.06) | n.s. |
| | | B*46:01 | 51.7 | 50.0 | 1.07 | (0.52 - 2.21) | n.s. |
| | | C*01:02 | 63.3 | 51.8 | 1.61 | (0.77 - 3.38) | n.s. |
| | | C*06:02 | 6.7 | 21.4 | 0.26 | (0.08 - 0.87) | n.s. |
| Present | Present | A*02:07 | 78.9 | 52.6 | 3.38 | (1.05 - 10.93) | n.s. |
| | | A*33:03 | 10.5 | 12.4 | 0.83 | (0.17 - 4.07) | n.s. |
| | | B*46:01 | 84.2 | 44.3 | 6.70 | (1.83 - 24.49) | <0.01 |
| | | C*01:02 | 78.9 | 53.6 | 3.25 | (1.00 - 10.49) | n.s. |
| | | C*06:02 | 5.3 | 15.5 | 0.30 | (0.04 - 2.45) | n.s. |

n.s.: not significant

¹*P*-values were corrected for multiple testing.